Vaxcyte, Inc. — Director's Dealing 2025

Jun 17, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2025-06-12

Reporting Person: Gilbert Halley E (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-06-12	Common Stock	A	3041	—	Acquired	10216	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-12	Stock Option (right to buy)	$34.46	A	15372	Acquired	2035-06-12	Common Stock (15372)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$5.35	2030-04-17	Common Stock (13500)	13500	Direct

Footnotes

F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.

F2: Option is fully vested and exercisable.

F3: On July 25, 2024, Reporting Person transferred 16,874 vested stock options to Reporting Person's ex-spouse pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. Accordingly, Reporting Person will not report beneficial ownership of or dispositions or acquisitions of the underlying shares in future Section 16(a) filings.

F4: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.